Week in Review | AstraZeneca's $2B Summit Bet, Merck's Eye Trial & Roche's Vamikibart Filing

<p>Merck's remigromig met BRUNELLO's noninferiority bar in diabetic macular edema, but showed no superiority and a notable safety imbalance. AstraZeneca completed its $2 billion Summit Therapeutics investment around ivonescimab combinations, while Roche's vamikibart entered FDA review with mixed Phase 3 evidence behind the filing. The Sunday, October 11 Week in Review—released Monday, October 12—also spans oncology, cardiometabolic and rare disease, respiratory and neuroscience, immunology, vaccines, infectious disease, access and medicine safety. Across 45 news stories and three forward watches, Alex and Maya separate completed events and clinical results from filings, plans and pending catalysts.</p><p><br /></p><p>Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.</p>